We submitted to the FDA the annual report about our LSD research. Annual reports are designed to give the FDA an overview of new developments. We reported on the progress from the first 4 subjects out of an eventual 12 in our Swiss LSD/end-of-life study. We were able to report that there were no drug-related Serious Adverse Events (SAEs) and that our research was conducted safely. Its too early to say anything about efficacy.
